Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Daxor Co. stock logo
DXR
Daxor
$9.89
+1.0%
$8.62
$7.11
$13.13
$46.88M-0.463,342 shs309 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$18.99
+2.4%
$17.62
$14.51
$22.99
$66.66M0.67,932 shs2,083 shs
Titan Medical Inc. stock logo
TMDI
Titan Medical
$0.14
-26.3%
$0.23
$0.13
$1.20
$15.67M2.364.83 million shs7.71 million shs
Minerva Surgical, Inc. stock logo
UTRS
Minerva Surgical
$0.41
-10.9%
$0.60
$0.30
$14.00
$3.64M0.671,349 shs3,058 shs
Venus Concept Inc. stock logo
VERO
Venus Concept
$0.77
-8.8%
$0.84
$0.60
$4.70
$4.90M0.66458,699 shs14,970 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Daxor Co. stock logo
DXR
Daxor
+0.41%+1.24%+17.81%+7.70%+978,999,900.00%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
-2.43%-2.26%+6.61%-14.56%+12.06%
Titan Medical Inc. stock logo
TMDI
Titan Medical
0.00%0.00%0.00%0.00%0.00%
Minerva Surgical, Inc. stock logo
UTRS
Minerva Surgical
-10.87%-26.79%-28.07%-58.16%-91.17%
Venus Concept Inc. stock logo
VERO
Venus Concept
0.00%+33.61%+18.12%-32.08%-73.17%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Daxor Co. stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/AN/AN/AN/A
Titan Medical Inc. stock logo
TMDI
Titan Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Minerva Surgical, Inc. stock logo
UTRS
Minerva Surgical
N/AN/AN/AN/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Daxor Co. stock logo
DXR
Daxor
N/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/A
Titan Medical Inc. stock logo
TMDI
Titan Medical
N/AN/AN/AN/A
Minerva Surgical, Inc. stock logo
UTRS
Minerva Surgical
N/AN/A$20.004,778.05% Upside
Venus Concept Inc. stock logo
VERO
Venus Concept
2.00
HoldN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Daxor Co. stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$46.09M1.45$2.24 per share8.48$8.91 per share2.13
Titan Medical Inc. stock logo
TMDI
Titan Medical
$20.09M0.78N/AN/A$0.32 per share0.44
Minerva Surgical, Inc. stock logo
UTRS
Minerva Surgical
$50.29M0.07N/AN/A$11.52 per share0.04
Venus Concept Inc. stock logo
VERO
Venus Concept
$76.35M0.06N/AN/A($2.43) per share-0.32

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Daxor Co. stock logo
DXR
Daxor
N/AN/A0.00N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$7.07M$0.7525.32N/A5.59%8.97%5.40%5/2/2024 (Estimated)
Titan Medical Inc. stock logo
TMDI
Titan Medical
-$14.86M-$0.19N/AN/AN/A-167.03%-112.15%N/A
Minerva Surgical, Inc. stock logo
UTRS
Minerva Surgical
-$34.11M-$8.21N/AN/A-64.71%-136.40%-43.70%4/30/2024 (Estimated)
Venus Concept Inc. stock logo
VERO
Venus Concept
-$37.25M-$6.85N/AN/AN/A-48.79%N/A-36.21%5/15/2024 (Confirmed)

Latest VERO, PDEX, DXR, TMDI, and UTRS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2024N/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/AN/A  
2/8/2024Q2 2024
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/A$0.14+$0.14$0.14N/A$12.59 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Daxor Co. stock logo
DXR
Daxor
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A
Titan Medical Inc. stock logo
TMDI
Titan Medical
N/AN/AN/AN/AN/A
Minerva Surgical, Inc. stock logo
UTRS
Minerva Surgical
N/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Daxor Co. stock logo
DXR
Daxor
N/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.26
3.66
2.16
Titan Medical Inc. stock logo
TMDI
Titan Medical
N/A
1.41
1.41
Minerva Surgical, Inc. stock logo
UTRS
Minerva Surgical
1.38
1.88
1.03
Venus Concept Inc. stock logo
VERO
Venus Concept
N/A
2.13
1.39

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Daxor Co. stock logo
DXR
Daxor
1.34%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%
Titan Medical Inc. stock logo
TMDI
Titan Medical
3.55%
Minerva Surgical, Inc. stock logo
UTRS
Minerva Surgical
N/A
Venus Concept Inc. stock logo
VERO
Venus Concept
87.41%

Insider Ownership

CompanyInsider Ownership
Daxor Co. stock logo
DXR
Daxor
60.60%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
42.60%
Titan Medical Inc. stock logo
TMDI
Titan Medical
0.02%
Minerva Surgical, Inc. stock logo
UTRS
Minerva Surgical
8.50%
Venus Concept Inc. stock logo
VERO
Venus Concept
51.39%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Daxor Co. stock logo
DXR
Daxor
N/A4.74 million1.87 millionNot Optionable
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
1453.51 million2.02 millionNot Optionable
Titan Medical Inc. stock logo
TMDI
Titan Medical
49111.95 million111.93 millionNot Optionable
Minerva Surgical, Inc. stock logo
UTRS
Minerva Surgical
1748.88 million8.12 millionNot Optionable
Venus Concept Inc. stock logo
VERO
Venus Concept
3046.36 million3.09 millionNot Optionable

VERO, PDEX, DXR, TMDI, and UTRS Headlines

SourceHeadline
Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
globenewswire.com - April 15 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
finanznachrichten.de - April 9 at 1:29 AM
Venus Concept Announces Approval For Venus Bliss MAX In Israel - Quick FactsVenus Concept Announces Approval For Venus Bliss MAX In Israel - Quick Facts
markets.businessinsider.com - April 8 at 10:21 AM
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
globenewswire.com - April 8 at 7:30 AM
Ranking every single MoonSwatch thats ever droppedRanking every single MoonSwatch that's ever dropped
gq-magazine.co.uk - April 3 at 10:37 PM
On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?
news.yahoo.com - April 3 at 10:37 PM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
finance.yahoo.com - April 3 at 7:36 AM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
globenewswire.com - April 3 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - April 2 at 9:35 PM
VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023
investorplace.com - April 1 at 1:03 PM
Venus Concept: Q4 Earnings SnapshotVenus Concept: Q4 Earnings Snapshot
houstonchronicle.com - April 1 at 9:42 AM
Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
globenewswire.com - April 1 at 7:00 AM
Venus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
finanznachrichten.de - March 26 at 2:33 AM
Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
globenewswire.com - March 25 at 7:30 AM
Venus Concept Launches "NEXThetics" ProgramVenus Concept Launches "NEXThetics" Program
stockhouse.com - March 13 at 10:30 AM
Venus Concept Launches “NEXThetics” ProgramVenus Concept Launches “NEXThetics” Program
globenewswire.com - March 12 at 4:05 PM
Venus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 27 at 4:05 PM
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 23 at 8:00 AM
Nasdaq Surges 300 Points; NVIDIA Posts Strong ResultsNasdaq Surges 300 Points; NVIDIA Posts Strong Results
msn.com - February 23 at 1:09 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
finance.yahoo.com - February 22 at 10:08 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
globenewswire.com - February 22 at 7:30 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
finance.yahoo.com - February 20 at 10:42 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
globenewswire.com - February 20 at 7:30 AM
Venus Concept Inc. to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13thVenus Concept Inc. to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13th
finance.yahoo.com - February 6 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Daxor logo

Daxor

NASDAQ:DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Pro-Dex logo

Pro-Dex

NASDAQ:PDEX
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Titan Medical logo

Titan Medical

NASDAQ:TMDI
Titan Medical, Inc. engages in the research and development of a computer-assisted robotic surgical technology for application in minimally invasive surgery (MIS). Its portfolio, the Enos™ system, is a robotic single access surgery with dual 3D and 2D definition vision systems, multi-articulating instruments, and a surgeon workstation. The company was founded on July 28, 2008 and is headquartered in Toronto, Canada.
Minerva Surgical logo

Minerva Surgical

NASDAQ:UTRS
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Venus Concept logo

Venus Concept

NASDAQ:VERO
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.